Welcome! Login | Register
 

Weiss: In 2050, Where Have All the Family Caregivers Gone?—Weiss: In 2050, Where Have All the Family…

Construction in Worcester - Week of April 23—Construction in Worcester - Week of April 23

Smart Benefits: CMS Releases HHS Notice of Benefit & Payment Parameters for 2019—Smart Benefits: CMS Releases HHS Notice of Benefit…

Holy Cross to Host Ribbon Cutting Ceremony for New Athletic Center—Holy Cross to Host Ribbon Cutting Ceremony for…

Celtics Comeback Falls Short, Lose to Bucks 104-102 in Game 4—Celtics Comeback Falls Short, Lose to Bucks 104-102…

Our First Ladies are a National Treasure – Sunday Political Brunch—April 22, 2018—Our First Ladies are a National Treasure –…

Monfredo: Powerful Documentary - Generation Zapped - A Must See This Thursday—Monfredo: Powerful Documentary - Generation Zapped - A…

Fit For Life: Stay Strong, Focused on Being Better at Everything—Fit For Life: Stay Strong, Focused on Being…

Bruins Rally Falls Short, Lose 4-3 to Maple Leafs in Game 5—Bruins Rally Falls Short, Lose 4-3 to Maple…

Revolution, Columbus Crew Play to 2-2 Draw—Revolution, Columbus Crew Play to 2-2 Draw

 
 

NEW: Mass to Receive $2.1 Million in Diabetes Drug Settlement

Thursday, November 15, 2012

 

Attorney General Martha Coakley’s Office has joined 37 other states in a $90 million settlement with GlaxoSmithKline LLC, resolving allegations that the pharmaceutical company unlawfully promoted its diabetes drug, Avandia, by misrepresenting its cardiovascular risks and safety profile. The settlement will bring more than $2.1 million to the Commonwealth.

“When pharmaceutical companies misrepresent the safety of their drugs, they put patients at risk,” AG Coakley said. “This settlement helps ensure that consumers will be protected from misleading marketing that can result in the unsafe use of prescription drugs.”

In order to increase their sales of Avandia in Massachusetts, the AG’s Office alleges that GlaxoSmithKline (GSK) promoted the diabetes drug to physicians and other health care providers with false and misleading representations about its safety and misrepresented the drug’s cardiovascular benefits when, in fact, the drug may instead increase risks.

Under the terms of the consent judgment, filed today in Suffolk Superior Court, GSK will pay more than $2.1 million to the Commonwealth including $100,000 for fees and investigative costs. The remaining funds will pay for programs that lower health care costs for Massachusetts residents, combat unlawful marketing practices in the health care market, or benefit health care consumers.

As part of the settlement, GSK agreed to reform how it markets and promotes diabetes drugs, and is prohibited from:

  • Making any false, misleading, or deceptive claims about any diabetes drug;
  • Making comparative safety claims not supported by substantial evidence or substantial clinical experience;
  • Presenting favorable information previously thought of as valid but rendered invalid by contrary and more credible recent information;
  • Promoting investigational drugs; or
  • Misusing statistics or otherwise misrepresenting the nature, applicability, or significance of clinical trials.
  • The consent judgment also imposes, for at least eight years, a number of requirements regarding GSK’s publication of the results of its studies, including that it register and post all GSK-sponsored clinical trials as required by federal law.

This consent judgment is in addition to a settlement announced in July when AG Coakley obtained more than $35 million from GlaxoSmithKline, on behalf of the Massachusetts Medicaid Program, due to its unlawful marketing of a number of drugs, including Avandia.

 

Related Articles

 

Enjoy this post? Share it with others.

 
Delivered Free Every
Day to Your Inbox